LOS ANGELES–(BUSINESS WIRE)–National partners join Donate Life Hollywood to help television and movies tell accurate stories concerning organ donation.
Author: Business Wire
Bluestone Sunshields Expands Offering from Fashionable Sun Protection to Functional Safety Wear as Businesses Begin Reopening
LOS ANGELES–(BUSINESS WIRE)–Bluestone Sunshields, the original chic solution to facial sun protection sold through dermatologist and esthetician offices, today announced a new product line of clear face shields as a back-to-work solution to protect w…
Ophthalmology Times® Is Now Accepting Nominations for the 2020 Research Scholar Honoree Program
CRANBURY, N.J.–(BUSINESS WIRE)– #Nominate–Finalists will be invited to the American Academy of Ophthalmology 2020 meeting in Las Vegas
Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pr…
Resumen: Diagnóstico con éxito de anticuerpos: Optics Balzers AG desarrolla filtros dieléctricos ópticos en el espectro UV
BALZERS, Liechtenstein–(BUSINESS WIRE)–La luz de onda corta, que va de 100 a 400 nm en el espectro UV, tiene la capacidad de luchar contra los patógenos. En los campos de la medicina esta propiedad se utiliza comúnmente para combatir gérmenes, bacter…
Riassunto: La diagnosi riuscita di anticorpi: Optics Balzers AG ha sviluppato ulteriormente filtri ottici dielettrici nello spettro ultravioletto
BALZERS, Liechtenstein–(BUSINESS WIRE)–La luce a onde corte, nella gamma compresa tra i 100 e i 400nm dello spettro UV, ha proprietà antimicrobiche. Nei campi medici, questa caratteristica viene comunemente utilizzata per combattere germi, batteri e …
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Wednesday, May 20, 2020 to provide a COVID-19 development update. The dial-in numbers are (866) 211-4098 for …
Erfolgreiche Diagnostik von Antikörpern: Die Optics Balzers AG hat optische dielektrische Filter im UV-Spektrum weiterentwickelt
BALZERS, Liechtenstein–(BUSINESS WIRE)–Kurzwelliges Licht im UV-Bereich von 100 bis 400 nm ist in der Lage, Erreger zu bekämpfen. In medizinischen Bereichen wird diese Eigenschaft gezielt genutzt, um die Anzahl der Keime, Bakterien und Viren zu reduz…
Samenvatting: Optics Balzers AG heeft optische diëlektrische filters verder ontwikkeld in het UV-spectrum
BALZERS, Liechtenstein–(BUSINESS WIRE)–Kortegolflicht, variërend van 100 tot 400 nm in het UV-spectrum, kan ziekteverwekkers bestrijden. Op medisch gebied wordt deze eigenschap vaak gebruikt om ziektekiemen, bacteriën en virussen te bestrijden. Studi…
Optics Balzers AG a développé des filtres diélectriques optiques dans le spectre UV, permettant de diagnostiquer les anticorps avec succès
BALZERS, Liechtenstein–(BUSINESS WIRE)–La lumière de courte longueur d’onde – de 100 à 400nm dans le spectre UV – possède la capacité de combattre les pathogènes. Dans l’environnement médical, cette propriété est couramment utilisée pour lutter contr…
Successful Diagnostics of Antibodies: Optics Balzers AG has Further Developed Optical Dielectric Filters in the UV Spectrum
BALZERS, Liechtenstein–(BUSINESS WIRE)– #UVFilter–Successful diagnostics of antibodies: Optics Balzers AG has further developed optical dielectric filters in the UV spectrum.
British Journal of Ophthalmology Publishes Strong EyeArt Accuracy Results
LOS ANGELES–(BUSINESS WIRE)– #NHS–Eyenuk, Inc. announced today that the British Journal of Ophthalmology published the research paper titled “Diagnostic Accuracy of Diabetic Retinopathy Grading by An Artificial Intelligence-Enabled Algorithm Compare…
Analysis on Impact of COVID19-Smart Glasses Market 2020-2024 | Implementation of Automation in Industrial Sector to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlobalSmartGlassesMarket–The smart glasses market size has the potential to grow by USD 59.94 million during 2020-2024
Alcon Prices US$750.0 Million Senior Notes Offering
GENEVA–(BUSINESS WIRE)–Alcon prices US$750.0 million senior notes offering
Kubota Vision Introduces Electronic Eyeglasses to Stop Myopia in Children
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced positive clinical results from myopia control t…
Avellino Announces A.C.T.S. Program to Help Eye Care and Other Surgical Practices Protect Patients and Staff From COVID-19
MENLO PARK, Calif.–(BUSINESS WIRE)– #avellinocoronatest–New COVID-19 safety program to help healthcare practices safely reopen and protect patients and staff from coronavirus, including test supply.
Ashvattha Therapeutics to Present at 2020 AACR Virtual Annual Meeting
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics to Present at 2020 AACR Virtual Annual Meeting
Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chie…
Samsung Bioepis Announces 24-week Interim Results from a Phase 3 Trial of SB11, Proposed Ranibizumab Biosimilar
INCHEON, Korea–(BUSINESS WIRE)–Samsung Bioepis Co., Ltd. announced today that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar cand…